Cellular Origins acquires Actia Platform IP to enhance automated cell therapy manufacturing

FHS
July 2, 2024
10:06 am

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge whilst CEO of SOTIO Biotech US. The ACTIA Platform complements Cellular Origins’ existing approach and will accelerate and expand R&D efforts to further develop the Company’s robotic solution for automated cell therapy manufacturing, Constellation™.

Q&A: How Flagship’s Cellarity is using AI to understand cell disease biology before treating it

Flagship Pioneering launched Cellarity in December 2019. The startup says it’s using artificial intelligence and other computational technologies “to move away from reductionist drug discovery,

June 26, 2024

Could your gut microbiome shape your teenage years? New study dives into the lifelong health impact

Research explores how the gut microbiota impacts critical areas of adolescent development, including mental health, metabolism, and skeletal growth. It suggests that understanding these interactions

September 7, 2023

BridgeBio’s big week, Lilly’s Alzheimer’s data, & succession at Stanford

What can Homer teach us about biotech? Has Big Science gotten too big? And what’s the future of treating Alzheimer’s disease? We cover all that

July 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.